Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Active Not Recruiting NCT06205628

Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension

Conditions: Hypertension, Hypertension,Essential

Sex: All

Ages: 18 Years – 65 Years

Healthy volunteers: No

Phase: PHASE1

Enrollment: 28

Sponsor: ADARx Pharmaceuticals, Inc.

Location: CMAX Clinical Research Adelaide South Australia

Summary

This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-850 in participants with hypertension.

Eligibility Criteria

Key Inclusion Criteria: * Body mass index (BMI) between 18 and 35 kg/m2 * Mild to moderate hypertension, mean of \>130 and \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06205628). StuddyBuddy aggregates publicly available trial information.